New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recommend Nucleic Acid Testing for Mycoplasma Genitalium
Retrieved on:
Monday, July 26, 2021
Medical devices, Medical Supplies, Women, Infectious diseases, Biotechnology, AIDS, Health, Consumer, General Health, Sexually transmitted diseases and infections, Medical specialties, Clinical medicine, Infectious causes of cancer, Medicine, Mycoplasma, Synthetic biology, Mycoplasma genitalium, Urethritis, Cervicitis, Nucleic acid test, Protein M
For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.
Key Points:
- For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.
- The 2015 CDC guidelines included M. genitalium as an emerging issue, but no FDA-cleared NAATs were available at that time11.
- Hologic was first to market in 2019 with a NAAT for M. genitalium, and Hologics Aptima Mycoplasma genitalium Assay is specifically noted in the current guidelines1.
- No FDA-cleared M. genitalium tests are available in the U.S. that detect antibiotic resistance, although Hologic is working to develop one.